NEW YORK (GenomeWeb) – CRISPR therapeutics firm Intellia Therapeutics on Thursday evening priced its previously announced initial public offering of six million shares of common stock at $18 per share. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the IPO price.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.